News

Aerie Pharmaceuticals announced Tuesday positive topline results for the phase 3 trial evaluating netarsudil 0.02% versus ripasudil 0.4% for the treatment of open-angle glaucoma and elevated IOP.

The FDA approved Ocular Therapeutix Inc.’s Supplemental New Drug Application (sNDA) that further extends Dextenza’s (dexamethasone ophthalmic insert) 0.4 mg indications, the company announced Monday.

Investigators in the United Kingdom found that concomitant vaccination of flu and COVID-19 raised no safety concerns and preserved the immune response to both vaccines.

According to 4D Molecular Therapeutics, it has received FDA Clearance of an IND Application for 4D-150, a dual-transgene intravitreal gene therapy for patients with wet AMD.

The company will move the highest dose of THR-149 (0.13mg) into Part B of the study based on favorable safety profile and positive efficacy data.

iCare USA’s EIDON Ultra-Widefield Lens module has received FDA 510 (k) approval for distribution across the United States, the company announced Wednesday.

The American Society of Retina Specialists (ASRS) will host its 39th Annual Scientific Meeting from October 8-12, 2021, at the JW Marriott San Antonio Hill Country Resort and Spa in San Antonio, Texas.

Investigators found evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks.

A team of investigators at the Texas Tech University Health Sciences Center have developed a technology derived from corneal epithelial stem cells to improve outcomes for DED patients.

According to researchers at the University of Virginia School of Medicine, common HIV drugs or a safer alternative could stop vision loss.

Researchers consider frequency and factors in etiology of complication

Study: Older age and eyes with severe nonproliferative diabetic retinopathy or proliferative diabetic retinopathy had a higher risk of a vision loss event.

Graybug Vision reported Tuesday a full-data analysis from the phase 2b ALTISSIMO trial of GB-102 for the treatment of wet AMD.

The screening device works by assessing the eyes’ ability to fixate together. Held 14 inches from the eyes, the child fixates on a smiley face while the device simultaneously scans both retinas.

Pfizer’s study will evaluate the investigational novel oral antiviral candidate PF-07321332 for the prevention of illness in adults living in the same household as someone with COVID-19.

Full year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab.

According to a survey commissioned by Allergan, an AbbVie company, 65% of respondents said they were not prepared to have their vision worsen as they aged.

In the weeks leading up to the October awareness day, the International Agency for the Prevention of Blindness has revealed a campaign to encourage one million people to pledge to have a vision test.

George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.

Addion GmbH has selected Stratasys technology to create realistic eye models for ophthalmic surgery.

Stanford University researchers released information indicating that in hospitalized patients with severe COVID-19, the virus can cause production of autoantibodies that can, in effect, cause the body to attack itself and result in inflammatory diseases.

Myopia is a global epidemic that is driven in part by educational pressures, especially in Asian populations.

American Society of Retinal Specialists program to drive awareness and action around retinal diseases that put millions at risk for blindness.

Orbis, with support from FedEx, is offering training that will develop ophthalmologists’ skills to treat diabetic retinopathy in China.

The company announced that inebilizumab-cdon produces rapid and sustained B-cell depletion in African Americans with neuromyelitis optica spectrum disorder.

A recent report by Heru Inc. has found that visual field (VF) results from re:Vive, its wearable testing platform, have a strong association to the ZEISS Humphrey Field Analyzer (HFA).

The eyeglasses were reportedly designed to help the wearer reach enlightenment and drive away evil, according to Sotheby’s London, which will host the auction next month.

Bath, who invented the Laserphaco Probe for treating cataracts, is the first African-American woman inducted into the National Inventors Hall of Fame.

Glaukos has entered into a licensing agreement with Attillaps Holdings Inc., giving it an exclusive license to research, develop, manufacture and commercialize Attillaps’ proprietary library of investigational pharmaceutical compounds that target the eradication of Demodex mites.

According to Samsung Bioepis and Biogen, ranibizumab-nuna becomes the first ophthalmology biosimilar to gain FDA approval in the United States.